Gongjian Zhu1, Haixiang Su2, Caroline H Johnson3, Sajid A Khan4, Harriet Kluger5, Lingeng Lu6. 1. Gansu Provincial Academy of Medical Science, Gansu Provincial Cancer Hospital, Lanzhou, 730050, China; Department of Chronic Disease Epidemiology, Yale School of Public Health, School of Medicine, Yale Cancer Center, Yale University, New Haven, CT, USA. 2. Gansu Provincial Academy of Medical Science, Gansu Provincial Cancer Hospital, Lanzhou, 730050, China. 3. Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, CT, USA. 4. Department of Surgery, Division of Surgical Oncology, Yale University School of Medicine, New Haven, CT, USA. 5. Department of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA. 6. Department of Chronic Disease Epidemiology, Yale School of Public Health, School of Medicine, Yale Cancer Center, Yale University, New Haven, CT, USA. Electronic address: lingeng.lu@yale.edu.
Abstract
OBJECTIVE: The gut microbiome plays an important role in systemic inflammation and immune response. Microbes can translocate and reside in tumour niches. However, it is unclear how the intratumour microbiome affects immunity in human cancer. The purpose of this study was to investigate the association between intratumour bacteria, infiltrating CD8+ T cells and patient survival in cutaneous melanoma. METHODS: Using The Cancer Genome Altas's cutaneous melanoma RNA sequencing data, levels of intratumour bacteria and infiltrating CD8+ T cells were determined. Correlation between intratumour bacteria and infiltrating CD8+ T cells or chemokine gene expression and survival analysis of infiltrating CD8+ T cells and Lachnoclostridium in cutaneous melanoma were performed. RESULTS: Patients with low levels of CD8+ T cells have significantly shorter survival than those with high levels. The adjusted hazard ratio was 1.57 (low vs high) (95% confidence interval: 1.17-2.10, p = 0.002). Intratumour bacteria of the Lachnoclostridium genus ranked top in a positive association with infiltrating CD8+ T cells (correlation coefficient = 0.38, p = 9.4 × 10-14), followed by Gelidibacter (0.31, p = 1.13 × 10-9), Flammeovirga (0.29, p = 1.96 × 10-8) and Acinetobacter (0.28, p = 8.94 × 10-8). These intratumour genera positively correlated with chemokine CXCL9, CXCL10 and CCL5 expression. The high Lachnoclostridium load significantly reduced the mortality risk (p = 0.0003). However, no statistically significant correlation was observed between intratumour Lachnoclostridium abundance and the levels of either NK, B or CD4+ T cells. CONCLUSION: Intratumour-residing gut microbiota could modulate chemokine levels and affect CD8+ T-cell infiltration, consequently influencing patient survival in cutaneous melanoma. Manipulating the intratumour gut microbiome may benefit patient outcomes for those undergoing immunotherapy.
OBJECTIVE: The gut microbiome plays an important role in systemic inflammation and immune response. Microbes can translocate and reside in tumour niches. However, it is unclear how the intratumour microbiome affects immunity in human cancer. The purpose of this study was to investigate the association between intratumour bacteria, infiltrating CD8+ T cells and patient survival in cutaneous melanoma. METHODS: Using The Cancer Genome Altas's cutaneous melanoma RNA sequencing data, levels of intratumour bacteria and infiltrating CD8+ T cells were determined. Correlation between intratumour bacteria and infiltrating CD8+ T cells or chemokine gene expression and survival analysis of infiltrating CD8+ T cells and Lachnoclostridium in cutaneous melanoma were performed. RESULTS: Patients with low levels of CD8+ T cells have significantly shorter survival than those with high levels. The adjusted hazard ratio was 1.57 (low vs high) (95% confidence interval: 1.17-2.10, p = 0.002). Intratumour bacteria of the Lachnoclostridium genus ranked top in a positive association with infiltrating CD8+ T cells (correlation coefficient = 0.38, p = 9.4 × 10-14), followed by Gelidibacter (0.31, p = 1.13 × 10-9), Flammeovirga (0.29, p = 1.96 × 10-8) and Acinetobacter (0.28, p = 8.94 × 10-8). These intratumour genera positively correlated with chemokine CXCL9, CXCL10 and CCL5 expression. The high Lachnoclostridium load significantly reduced the mortality risk (p = 0.0003). However, no statistically significant correlation was observed between intratumour Lachnoclostridium abundance and the levels of either NK, B or CD4+ T cells. CONCLUSION: Intratumour-residing gut microbiota could modulate chemokine levels and affect CD8+ T-cell infiltration, consequently influencing patient survival in cutaneous melanoma. Manipulating the intratumour gut microbiome may benefit patient outcomes for those undergoing immunotherapy.
Authors: Harriet M Kluger; Christopher R Zito; Meaghan L Barr; Marina K Baine; Veronica L S Chiang; Mario Sznol; David L Rimm; Lieping Chen; Lucia B Jilaveanu Journal: Clin Cancer Res Date: 2015-03-18 Impact factor: 12.531
Authors: Georgina V Long; Richard A Scolyer; Umaimainthan Palendira; Jarem Edwards; James S Wilmott; Jason Madore; Tuba Nur Gide; Camelia Quek; Annie Tasker; Angela Ferguson; Jinbiao Chen; Rehana Hewavisenti; Peter Hersey; Thomas Gebhardt; Wolfgang Weninger; Warwick J Britton; Robyn P M Saw; John F Thompson; Alexander M Menzies Journal: Clin Cancer Res Date: 2018-03-29 Impact factor: 12.531
Authors: Tuba N Gide; Camelia Quek; Alexander M Menzies; Annie T Tasker; Ping Shang; Jeff Holst; Jason Madore; Su Yin Lim; Rebecca Velickovic; Matthew Wongchenko; Yibing Yan; Serigne Lo; Matteo S Carlino; Alexander Guminski; Robyn P M Saw; Angel Pang; Helen M McGuire; Umaimainthan Palendira; John F Thompson; Helen Rizos; Ines Pires da Silva; Marcel Batten; Richard A Scolyer; Georgina V Long; James S Wilmott Journal: Cancer Cell Date: 2019-02-11 Impact factor: 31.743
Authors: Matthew H Spitzer; Yaron Carmi; Nathan E Reticker-Flynn; Serena S Kwek; Deepthi Madhireddy; Maria M Martins; Pier Federico Gherardini; Tyler R Prestwood; Jonathan Chabon; Sean C Bendall; Lawrence Fong; Garry P Nolan; Edgar G Engleman Journal: Cell Date: 2017-01-19 Impact factor: 41.582
Authors: Ricardo E Vilain; Alexander M Menzies; James S Wilmott; Hojabr Kakavand; Jason Madore; Alexander Guminski; Elizabeth Liniker; Benjamin Y Kong; Adam J Cooper; Julie R Howle; Robyn P M Saw; Valerie Jakrot; Serigne Lo; John F Thompson; Matteo S Carlino; Richard F Kefford; Georgina V Long; Richard A Scolyer Journal: Clin Cancer Res Date: 2017-05-16 Impact factor: 12.531
Authors: Vancheswaran Gopalakrishnan; Beth A Helmink; Christine N Spencer; Alexandre Reuben; Jennifer A Wargo Journal: Cancer Cell Date: 2018-04-09 Impact factor: 31.743
Authors: Daniela Massi; Eliana Rulli; Mara Cossa; Barbara Valeri; Monica Rodolfo; Barbara Merelli; Francesco De Logu; Romina Nassini; Michele Del Vecchio; Lorenza Di Guardo; Roberta De Penni; Michele Guida; Vanna Chiarion Sileni; Anna Maria Di Giacomo; Marco Tucci; Marcella Occelli; Francesca Portelli; Viviana Vallacchi; Francesca Consoli; Pietro Quaglino; Paola Queirolo; Gianna Baroni; Fabrizio Carnevale-Schianca; Laura Cattaneo; Alessandro Minisini; Giuseppe Palmieri; Licia Rivoltini; Mario Mandalà Journal: J Immunother Cancer Date: 2019-11-15 Impact factor: 13.751
Authors: Yuping Cai; Xinyi Shen; Lingeng Lu; Hong Yan; Huang Huang; Patricia Gaule; Engjel Muca; Casey M Theriot; Zahra Rattray; Nicholas J W Rattray; Jun Lu; Nita Ahuja; Yawei Zhang; Philip B Paty; Sajid A Khan; Caroline H Johnson Journal: Biol Sex Differ Date: 2022-10-23 Impact factor: 8.811
Authors: Yadav S Bajagai; Friedrich Petranyi; Sung J Yu; Edina Lobo; Romeo Batacan; Advait Kayal; Darwin Horyanto; Xipeng Ren; Maria M Whitton; Dragana Stanley Journal: Sci Rep Date: 2022-06-30 Impact factor: 4.996
Authors: Kara T Kleber; Khurshid R Iranpur; Lauren M Perry; Sylvia M Cruz; Aryana M Razmara; William T N Culp; Michael S Kent; Jonathan A Eisen; Robert B Rebhun; Robert J Canter Journal: Front Immunol Date: 2022-08-12 Impact factor: 8.786